ES2193111T3 - Forma retardada que contiene (derivados de ) acido alfalipoico. - Google Patents

Forma retardada que contiene (derivados de ) acido alfalipoico.

Info

Publication number
ES2193111T3
ES2193111T3 ES00969359T ES00969359T ES2193111T3 ES 2193111 T3 ES2193111 T3 ES 2193111T3 ES 00969359 T ES00969359 T ES 00969359T ES 00969359 T ES00969359 T ES 00969359T ES 2193111 T3 ES2193111 T3 ES 2193111T3
Authority
ES
Spain
Prior art keywords
derivatives
retard form
form containing
acid
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00969359T
Other languages
English (en)
Inventor
Hans Schuhbauer
Ivo Pischel
Andreas Bernkop-Schnurch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10045904A external-priority patent/DE10045904B4/de
Application filed by Degussa GmbH filed Critical Degussa GmbH
Application granted granted Critical
Publication of ES2193111T3 publication Critical patent/ES2193111T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Forma retardada que contiene: (a) Uno o varios polímeros cationógenos, (b) Ácido -lipoico o/y un derivado del mismo, y (c) Al menos un ácido distinto de (b).
ES00969359T 1999-10-01 2000-09-29 Forma retardada que contiene (derivados de ) acido alfalipoico. Expired - Lifetime ES2193111T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947330 1999-10-01
DE10045904A DE10045904B4 (de) 1999-10-01 2000-09-16 alpha-Liponsäure(-Derivate) enthaltende Retardform

Publications (1)

Publication Number Publication Date
ES2193111T3 true ES2193111T3 (es) 2003-11-01

Family

ID=26007080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00969359T Expired - Lifetime ES2193111T3 (es) 1999-10-01 2000-09-29 Forma retardada que contiene (derivados de ) acido alfalipoico.

Country Status (10)

Country Link
EP (1) EP1216043B1 (es)
JP (1) JP2003510358A (es)
CN (1) CN1232252C (es)
AT (1) ATE239469T1 (es)
AU (1) AU7911000A (es)
CA (1) CA2385867C (es)
DK (1) DK1216043T3 (es)
ES (1) ES2193111T3 (es)
PT (1) PT1216043E (es)
WO (1) WO2001024795A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180337A1 (en) * 2000-06-06 2003-09-25 Harald Streicher Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals
KR101100803B1 (ko) * 2009-04-24 2011-12-29 서울과학기술대학교 산학협력단 리포아마이드가 결합된 고분자화합물과 이의 제조방법
CN101665569B (zh) * 2009-07-23 2011-09-28 苏州大学 侧链用硫辛酸修饰的亲水性聚合物及其制备和应用
CN102212146B (zh) * 2009-07-23 2013-02-13 苏州大学 一种侧链用硫辛酸修饰的亲水性聚合物
CN107789350A (zh) * 2016-08-31 2018-03-13 杜建 包含硫辛酸及/或其衍生物的组合物及其应用
CN110387142B (zh) * 2019-08-14 2021-08-17 桂林理工大学 一种负载有脂溶性色素的桃胶多糖纳米球的制备方法
CN114656616A (zh) * 2022-03-31 2022-06-24 深圳先进技术研究院 一种基于硫辛酸或/和其衍生物的本征型自修复的导热高分子聚合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61293931A (ja) * 1985-06-24 1986-12-24 Teijin Ltd 徐放性医薬品組成物
JPS63101332A (ja) * 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
SE508601C2 (sv) * 1989-11-09 1998-10-19 Asta Medica Ag Läkemedel, vilka som aktiv substans innehåller karboxylsyror innehållande svavel samt deras användning för bekämpning av retrovirus
JPH0418036A (ja) * 1990-05-09 1992-01-22 Kurita Water Ind Ltd 薬剤組成物
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
JPH06293801A (ja) * 1993-04-07 1994-10-21 Nippon Suisan Kaisha Ltd アルカリ域でも水溶解性を示すキトサン及びその製造方法
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit

Also Published As

Publication number Publication date
PT1216043E (pt) 2003-09-30
CN1377267A (zh) 2002-10-30
CA2385867A1 (en) 2001-04-12
EP1216043A1 (de) 2002-06-26
AU7911000A (en) 2001-05-10
EP1216043B1 (de) 2003-05-07
WO2001024795A1 (de) 2001-04-12
CA2385867C (en) 2009-09-01
JP2003510358A (ja) 2003-03-18
CN1232252C (zh) 2005-12-21
ATE239469T1 (de) 2003-05-15
DK1216043T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
ATE255589T1 (de) Kristallin form i von clarithromycin
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
BG102259A (en) Compostions with controlled paroxetine release
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2002004409A3 (en) Tetrahydrobenzothiazole analogues as neuroprotective agents
EP1319402A4 (en) IgE FORMATION INHIBITORS
TWI256292B (en) Reduction inhibitory agent for active oxygen eliminating activity
ES2193111T3 (es) Forma retardada que contiene (derivados de ) acido alfalipoico.
DE60017361D1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
WO2004073675A8 (de) Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
EA200100930A1 (ru) Способ лечения хозл
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
NO965258D0 (no) Legemiddelsalter
WO1996028151A3 (en) Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs
PT1181300E (pt) Derivados 6-o-carbamato de cetolido
YU31499A (sh) Proces za dobijanje jedinjenja pirolidinil hidroksamske kiseline
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
TW200505872A (en) Hepatitis C virus inhibitors
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
DE69626307D1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor
BR0011742A (pt) Proteção bacteriana
WO2001032616A3 (en) Oxetanone derivatives